Search

Your search keyword '"Larson A"' showing total 2,640 results
Start Over Author "Larson A" Journal blood
2,640 results on '"Larson A"'

1. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand

Author

Nicolai, Christopher J., Parker, Maura H., Qin, Jim, Tang, Weiliang, Ulrich-Lewis, Justin T., Gottschalk, Rebecca J., Cooper, Sara E., Hernandez Lopez, Susana A., Parrilla, Don, Mangio, Richard S., Ericson, Nolan G., Brandes, Alissa H., Umuhoza, Saluwa, Michels, Kathryn R., McDonnell, Mollie M., Park, Lisa Y., Shin, Seungjin, Leung, Wai-Hang, Scharenberg, Andrew M., Kiem, Hans-Peter, Larson, Ryan P., Beitz, Laurie O., and Ryu, Byoung Y.

Published
2024
Full Text
View/download PDF

2. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

Author

Woyach, Jennifer A., Perez Burbano, Gabriela, Ruppert, Amy S., Miller, Cecelia, Heerema, Nyla A., Zhao, Weiqiang, Wall, Anna, Ding, Wei, Bartlett, Nancy L., Brander, Danielle M., Barr, Paul M., Rogers, Kerry A., Parikh, Sameer A., Stephens, Deborah M., Brown, Jennifer R., Lozanski, Gerard, Blachly, James, Nattam, Sreenivasa, Larson, Richard A., Erba, Harry, Litzow, Mark, Luger, Selina, Owen, Carolyn, Kuzma, Charles, Abramson, Jeremy S., Little, Richard F., Dinner, Shira, Stone, Richard M., Uy, Geoffrey, Stock, Wendy, Mandrekar, Sumithra J., and Byrd, John C.

Published
2024
Full Text
View/download PDF

4. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Author

Badros, Ashraf, Foster, Laahn, Anderson, Larry D., Chaulagain, Chakra P., Pettijohn, Erin, Cowan, Andrew J., Costello, Caitlin, Larson, Sarah, Sborov, Douglas W., Shain, Kenneth H., Silbermann, Rebecca, Shah, Nina, Chung, Alfred, Krevvata, Maria, Pei, Huiling, Patel, Sharmila, Khare, Vipin, Cortoos, Annelore, Carson, Robin, Lin, Thomas S., and Voorhees, Peter

Published
2024
Full Text
View/download PDF

5. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Author

de Botton, Stéphane, Montesinos, Pau, Schuh, Andre C., Papayannidis, Cristina, Vyas, Paresh, Wei, Andrew H., Ommen, Hans, Semochkin, Sergey, Kim, Hee-Je, Larson, Richard A., Koprivnikar, Jaime, Frankfurt, Olga, Thol, Felicitas, Chromik, Jörg, Byrne, Jenny, Pigneux, Arnaud, Thomas, Xavier, Salamero, Olga, Vidriales, Maria Belen, Doronin, Vadim, Döhner, Hartmut, Fathi, Amir T., Laille, Eric, Yu, Xin, Hasan, Maroof, Martin-Regueira, Patricia, and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

6. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Author

Döhner, Hartmut, Wei, Andrew H., Appelbaum, Frederick R., Craddock, Charles, DiNardo, Courtney D., Dombret, Hervé, Ebert, Benjamin L., Fenaux, Pierre, Godley, Lucy A., Hasserjian, Robert P., Larson, Richard A., Levine, Ross L., Miyazaki, Yasushi, Niederwieser, Dietger, Ossenkoppele, Gert, Röllig, Christoph, Sierra, Jorge, Stein, Eytan M., Tallman, Martin S., Tien, Hwei-Fang, Wang, Jianxiang, Wierzbowska, Agnieszka, and Löwenberg, Bob

Published
2022
Full Text
View/download PDF

7. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Author

Arber, Daniel A., Orazi, Attilio, Hasserjian, Robert P., Borowitz, Michael J., Calvo, Katherine R., Kvasnicka, Hans-Michael, Wang, Sa A., Bagg, Adam, Barbui, Tiziano, Branford, Susan, Bueso-Ramos, Carlos E., Cortes, Jorge E., Dal Cin, Paola, DiNardo, Courtney D., Dombret, Hervé, Duncavage, Eric J., Ebert, Benjamin L., Estey, Elihu H., Facchetti, Fabio, Foucar, Kathryn, Gangat, Naseema, Gianelli, Umberto, Godley, Lucy A., Gökbuget, Nicola, Gotlib, Jason, Hellström-Lindberg, Eva, Hobbs, Gabriela S., Hoffman, Ronald, Jabbour, Elias J., Kiladjian, Jean-Jacques, Larson, Richard A., Le Beau, Michelle M., Loh, Mignon L.-C., Löwenberg, Bob, Macintyre, Elizabeth, Malcovati, Luca, Mullighan, Charles G., Niemeyer, Charlotte, Odenike, Olatoyosi M., Ogawa, Seishi, Orfao, Alberto, Papaemmanuil, Elli, Passamonti, Francesco, Porkka, Kimmo, Pui, Ching-Hon, Radich, Jerald P., Reiter, Andreas, Rozman, Maria, Rudelius, Martina, Savona, Michael R., Schiffer, Charles A., Schmitt-Graeff, Annette, Shimamura, Akiko, Sierra, Jorge, Stock, Wendy A., Stone, Richard M., Tallman, Martin S., Thiele, Jürgen, Tien, Hwei-Fang, Tzankov, Alexandar, Vannucchi, Alessandro M., Vyas, Paresh, Wei, Andrew H., Weinberg, Olga K., Wierzbowska, Agnieszka, Cazzola, Mario, Döhner, Hartmut, and Tefferi, Ayalew

Published
2022
Full Text
View/download PDF

8. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma

Author

Sakemura, Reona, Hefazi, Mehrdad, Siegler, Elizabeth L., Cox, Michelle J., Larson, Daniel P., Hansen, Michael J., Manriquez Roman, Claudia, Schick, Kendall J., Can, Ismail, Tapper, Erin E., Horvei, Paulina, Adada, Mohamad M., Bezerra, Evandro D., Kankeu Fonkoua, Lionel Aurelien, Ruff, Michael W., Nevala, Wendy K., Walters, Denise K., Parikh, Sameer A., Lin, Yi, Jelinek, Diane F., Kay, Neil E., Bergsagel, P. Leif, and Kenderian, Saad S.

Published
2022
Full Text
View/download PDF

9. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Author

Perl, Alexander E., Larson, Richard A., Podoltsev, Nikolai A., Strickland, Stephen, Wang, Eunice S., Atallah, Ehab, Schiller, Gary J., Martinelli, Giovanni, Neubauer, Andreas, Sierra, Jorge, Montesinos, Pau, Récher, Christian, Yoon, Sung-Soo, Hosono, Naoko, Onozawa, Masahiro, Chiba, Shigeru, Kim, Hee-Je, Hasabou, Nahla, Lu, Qiaoyang, Tiu, Ramon, and Levis, Mark J.

Published
2022
Full Text
View/download PDF

10. Structural racism is a mediator of disparities in acute myeloid leukemia outcomes

Author

Abraham, Ivy Elizabeth, Rauscher, Garth H., Patel, Anand Ashwin, Pearse, William B., Rajakumar, Priya, Burkart, Madelyn, Aleem, Ahmed, Dave, Ami, Bharadwaj, Sushma, Paydary, Koosha, Acevedo-Mendez, Maria, Goparaju, Krishna, Gomez, Richard, Carlson, Kylie, Tsai, Stephanie B., Quigley, John G., Galvin, John P., Zia, Maryam, Larson, Melissa L., Berg, Stephanie, Stock, Wendy, Altman, Jessica K., and Khan, Irum

Published
2022
Full Text
View/download PDF

11. HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Author

Thompson, James E, primary, Gao, Yan, additional, Visotcky, Alexis, additional, Flynn, Kathryn E, additional, Mauro, Michael, additional, Giever, Emily, additional, Baim, Arielle, additional, Akinola, Idayat, additional, Larson, Richard, additional, Jamy, Omer, additional, Hunter, Anthony M., additional, Kota, Vamsi K., additional, Cortes, Jorge, additional, Druker, Brian J., additional, Shah, Neil P., additional, Pinilla-Ibarz, Javier, additional, Yang, Jay, additional, Ritchie, Ellen K., additional, Rein, Lindsay A.M, additional, Smith, B. Douglas, additional, Tantravahi, Srinivas K., additional, Badar, Talha, additional, Deininger, Michael W., additional, and Atallah, Ehab L., additional

Published
2023
Full Text
View/download PDF

12. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia

Author

Giacopelli, Brian, Zhao, Qiuhong, Ruppert, Amy S., Agyeman, Akwasi, Weigel, Christoph, Wu, Yue-Zhong, Gerber, Madelyn M., Rabe, Kari G., Larson, Melissa C., Lu, Junyan, Blachly, James S., Rogers, Kerry A., Wierda, William G., Brown, Jennifer R., Rai, Kanti R., Keating, Michael, Rassenti, Laura Z., Kipps, Thomas J., Zenz, Thorsten, Shanafelt, Tait D., Kay, Neil E., Abruzzo, Lynne V., Coombes, Kevin R., Woyach, Jennifer A., Byrd, John C., and Oakes, Christopher C.

Published
2019
Full Text
View/download PDF

13. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Author

Stock, Wendy, Luger, Selina M., Advani, Anjali S., Yin, Jun, Harvey, Richard C., Mullighan, Charles G., Willman, Cheryl L., Fulton, Noreen, Laumann, Kristina M., Malnassy, Greg, Paietta, Elisabeth, Parker, Edy, Geyer, Susan, Mrózek, Krzysztof, Bloomfield, Clara D., Sanford, Ben, Marcucci, Guido, Liedtke, Michaela, Claxton, David F., Foster, Matthew C., Bogart, Jeffrey A., Grecula, John C., Appelbaum, Frederick R., Erba, Harry, Litzow, Mark R., Tallman, Martin S., Stone, Richard M., and Larson, Richard A.

Published
2019
Full Text
View/download PDF

14. Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma

Author

Juan Pablo Alderuccio, Isildinha M. Reis, Jean L. Koff, Melissa C. Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M. Habermann, Peter Martin, Jennifer R. Chapman, Christopher Strouse, Brad S. Kahl, Jonathon B. Cohen, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, and Izidore S. Lossos

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2023

15. Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Author

Hongtao Liu, Elad Sharon, Theodore G. Karrison, Yuanyuan Zha, Noreen Fulton, Howard Streicher, Kendra Sweet, George Yaghmour, Jane Jijun Liu, Brian A. Jonas, Aaron D. Schimmer, Steven Grant, Amer M. Zeidan, Gerhard C. Hildebrandt, Christopher S. Hourigan, Christopher H. Lowrey, Ryan J. Mattison, Neil Palmisiano, Amandeep Salhotra, Dimitrios Tzachanis, Maria R. Baer, Tara L. Lin, Prapti Patel, Helen Chen, Walter M. Stadler, Olatoyosi Odenike, Richard A. Larson, Thomas F. Gajewski, and Wendy Stock

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

16. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

Author

Mantha, Simon, Goldman, Debra A., Devlin, Sean M., Lee, Ju-Whei, Zannino, Diana, Collins, Marnie, Douer, Dan, Iland, Harry J., Litzow, Mark R., Stein, Eytan M., Appelbaum, Frederick R., Larson, Richard A., Stone, Richard, Powell, Bayard L., Geyer, Susan, Laumann, Kristina, Rowe, Jacob M., Erba, Harry, Coutre, Steven, Othus, Megan, Park, Jae H., Wiernik, Peter H., and Tallman, Martin S.

Published
2017
Full Text
View/download PDF

17. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Author

Döhner, Hartmut, Estey, Elihu, Grimwade, David, Amadori, Sergio, Appelbaum, Frederick R., Büchner, Thomas, Dombret, Hervé, Ebert, Benjamin L., Fenaux, Pierre, Larson, Richard A., Levine, Ross L., Lo-Coco, Francesco, Naoe, Tomoki, Niederwieser, Dietger, Ossenkoppele, Gert J., Sanz, Miguel, Sierra, Jorge, Tallman, Martin S., Tien, Hwei-Fang, Wei, Andrew H., Löwenberg, Bob, and Bloomfield, Clara D.

Published
2017
Full Text
View/download PDF

18. Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Author

Abro, Brooj, Maurer, Matthew J., Habermann, Thomas M., Burack, W. Richard, Chapman, Jennifer R., Cohen, Jonathon B., Friedberg, Jonathan W., Inghirami, Giorgio, Kahl, Brad S., Larson, Melissa C., Link, Brian K., Lossos, Izidore S., Martin, Peter, McDonnell, Timothy J., Nastoupil, Loretta J., Riska, Shaun M., Syrbu, Sergei, Vega, Francisco, Vij, Kiran R., Flowers, Christopher R., Cerhan, James R., Jaye, David L., and Feldman, Andrew L.

Published
2024
Full Text
View/download PDF

19. Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting

Author

Jennifer Jane Gile, Allison M. Bock, Reema K. Tawfiq, Melissa C. Larson, Kittika Poonsombudlert, Seth M. Maliske, Matthew J. Maurer, James R. Cerhan, Brian Kabat, Brianna Gysbers, Katherine Smith, Steven R Hwang, David J. Inwards, Jonas Paludo, Stephen M. Ansell, Thomas M. Habermann, Sabarish Ayyappan, Thomas E. Witzig, Grzegorz S. Nowakowski, Umar Farooq, and Yucai Wang

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

21. Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma

Author

Reema K. Tawfiq, Melissa C. Larson, Jennifer Jane Gile, Allison M. Bock, Kittika Poonsombudlert, Seth M. Maliske, Matthew J. Maurer, James R. Cerhan, Brian Kabat, Katherine Smith, Richard Curtis Godby, Jonas Paludo, David J. Inwards, Sabarish Ayyappan, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Umar Farooq, and Yucai Wang

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

23. Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study

Author

Jia Ruan, Melissa C. Larson, Zhengming Chen, N. Nora Bennani, Pamela B. Allen, David L Jaye, Jonathon B. Cohen, Dai Chihara, Francisco Vega, Giorgio Inghirami, Eric Mou, Carla Casulo, Neha Mehta-Shah, Peter Martin, Matthew J. Maurer, Brad S. Kahl, Izidore S. Lossos, Christopher R. Flowers, James R. Cerhan, and Andrew L. Feldman

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

24. Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers

Author

Emily Symes, Zhihong Hu, Stephen K. Walker, Vishakha Sovani, Nicolas Lopez-Hisijos, Barina Aqil, Mir Alikhan, Claudiu V. Cotta, Sean Harrop, Angela Lager, Beenu Thakral, Peter A. Riedell, Carrie Fitzpatrick, Michael J. Thirman, Anand Ashwin Patel, Caner Saygin, Sandra L. Ondrejka, Michael R. Bishop, Amir Behdad, Sandeep Gurbuxani, Daniel A. Arber, M. James You, Richard A. Larson, Sonali M. Smith, Yan Amber Hodgson, Justin Kline, Matthew Ku, and Girish Venkataraman

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

25. Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis

Author

Caner Saygin, Jacob Stauber, Ibrahim Aldoss, Adam S. Sperling, Lachelle D. Weeks, Marlise R. Luskin, Todd C. Knepper, Pankhuri Wanjari, Peng Wang, Angela Lager, Jeremy Segal, Benjamin Kaumeyer, Sandeep Gurbuxani, Girish Venkataraman, Jason Xiaojun Cheng, Bartholomew Eisfelder, Oliver Bohorquez, Anand Ashwin Patel, Olatoyosi Odenike, Richard A. Larson, Lucy A. Godley, Daniel A. Arber, Benjamin L. Ebert, John M. Greally, Ulrich G. Steidl, Bijal D. Shah, and Wendy Stock

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

26. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma

Author

Reona Sakemura, Mehrdad Hefazi, Elizabeth L. Siegler, Michelle J. Cox, Daniel P. Larson, Michael J. Hansen, Claudia Manriquez Roman, Kendall J. Schick, Ismail Can, Erin E. Tapper, Paulina Horvei, Mohamad M. Adada, Evandro D. Bezerra, Lionel Aurelien Kankeu Fonkoua, Michael W. Ruff, Wendy K. Nevala, Denise K. Walters, Sameer A. Parikh, Yi Lin, Diane F. Jelinek, Neil E. Kay, P. Leif Bergsagel, and Saad S. Kenderian

Subjects
Immunology, Cell- and Tissue-Based Therapy, virus diseases, Cell Biology, Hematology, Fibroblasts, Immunotherapy, Adoptive, Biochemistry, Cancer-Associated Fibroblasts, Bone Marrow, immune system diseases, mental disorders, Tumor Microenvironment, Humans, Multiple Myeloma
Abstract

Pivotal clinical trials of B-cell maturation antigen-targeted chimeric antigen receptor T (CART)-cell therapy in patients with relapsed/refractory multiple myeloma (MM) resulted in remarkable initial responses, which led to a recent US Food and Drug Administration approval. Despite the success of this therapy, durable remissions continue to be low, and the predominant mechanism of resistance is loss of CART cells and inhibition by the tumor microenvironment (TME). MM is characterized by an immunosuppressive TME with an abundance of cancer-associated fibroblasts (CAFs). Using MM models, we studied the impact of CAFs on CART-cell efficacy and developed strategies to overcome CART-cell inhibition. We showed that CAFs inhibit CART-cell antitumor activity and promote MM progression. CAFs express molecules such as fibroblast activation protein and signaling lymphocyte activation molecule family-7, which are attractive immunotherapy targets. To overcome CAF-induced CART-cell inhibition, CART cells were generated targeting both MM cells and CAFs. This dual-targeting CART-cell strategy significantly improved the effector functions of CART cells. We show for the first time that dual targeting of both malignant plasma cells and the CAFs within the TME is a novel strategy to overcome resistance to CART-cell therapy in MM.

Published
2022

27. Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., additional, Koff, Jean L., additional, Larson, Melissa C., additional, Chihara, Dai, additional, Zhao, Wei, additional, Haddadi, Sara, additional, Habermann, Thomas M., additional, Martin, Peter, additional, Chapman, Jennifer R., additional, Strouse, Christopher, additional, Kahl, Brad S., additional, Cohen, Jonathon B., additional, Friedberg, Jonathan W., additional, Cerhan, James R., additional, Flowers, Christopher R., additional, and Lossos, Izidore S., additional

Published
2023
Full Text
View/download PDF

28. Structural racism is a mediator of disparities in acute myeloid leukemia outcomes

Author

Ivy Elizabeth Abraham, Garth H. Rauscher, Anand Ashwin Patel, William B. Pearse, Priya Rajakumar, Madelyn Burkart, Ahmed Aleem, Ami Dave, Sushma Bharadwaj, Koosha Paydary, Maria Acevedo-Mendez, Krishna Goparaju, Richard Gomez, Kylie Carlson, Stephanie B. Tsai, John G. Quigley, John P. Galvin, Maryam Zia, Melissa L. Larson, Stephanie Berg, Wendy Stock, Jessica K. Altman, and Irum Khan

Subjects
Adult, Leukemia, Myeloid, Acute, Immunology, Ethnicity, Humans, Health Status Disparities, Hispanic or Latino, Cell Biology, Hematology, Biochemistry, White People, Systemic Racism
Abstract

Non-Hispanic Black (NHB) and Hispanic patients with acute myeloid leukemia (AML) have higher mortality rates than non-Hispanic White (NHW) patients despite more favorable genetics and younger age. A discrete survival analysis was performed on 822 adult patients with AML from 6 urban cancer centers and revealed inferior survival among NHB (hazard ratio [HR] = 1.59; 95% confidence interval [CI]: 1.15, 2.22) and Hispanic (HR = 1.25; 95% CI: 0.88, 1.79) patients compared with NHW patients. A multilevel analysis of disparities was then conducted to investigate the contribution of neighborhood measures of structural racism on racial/ethnic differences in survival. Census tract disadvantage and affluence scores were individually calculated. Mediation analysis of hazard of leukemia death between groups was examined across 6 composite variables: structural racism (census tract disadvantage, affluence, and segregation), tumor biology (European Leukemia Network risk and secondary leukemia), health care access (insurance and clinical trial enrollment), comorbidities, treatment patterns (induction intensity and transplant utilization), and intensive care unit (ICU) admission during induction chemotherapy. Strikingly, census tract measures accounted for nearly all of the NHB-NHW and Hispanic-NHW disparity in leukemia death. Treatment patterns, including induction intensity and allogeneic transplant, and treatment complications, as assessed by ICU admission during induction chemotherapy, were additional mediators of survival disparities in AML. This is the first study to formally test mediators for observed disparities in AML survival and highlights the need to investigate the mechanisms by which structural racism interacts with known prognostic and treatment factors to influence leukemia outcomes.

Published
2022

30. Overexpression and knockout of miR-126 both promote leukemogenesis

Author

Li, Zejuan, Chen, Ping, Su, Rui, Li, Yuanyuan, Hu, Chao, Wang, Yungui, Arnovitz, Stephen, He, Miao, Gurbuxani, Sandeep, Zuo, Zhixiang, Elkahloun, Abdel G., Li, Shenglai, Weng, Hengyou, Huang, Hao, Neilly, Mary Beth, Wang, Shusheng, Olson, Eric N., Larson, Richard A., Le Beau, Michelle M., Zhang, Jiwang, Jiang, Xi, Wei, Minjie, Jin, Jie, Liu, Paul P., and Chen, Jianjun

Published
2015
Full Text
View/download PDF

31. Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M, additional, Koff, Jean L., additional, Larson, Melissa C., additional, Chihara, Dai, additional, Zhao, Wei, additional, Haddadi, Sara, additional, Habermann, Thomas M., additional, Martin, Peter, additional, Chapman-Fredricks, Jennifer R, additional, Strouse, Christopher, additional, Kahl, Brad S., additional, Cohen, Jonathon B., additional, Friedberg, Jonathan W., additional, Cerhan, James R., additional, Flowers, Christopher R., additional, and Lossos, Izidore S., additional

Published
2022
Full Text
View/download PDF

33. Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Author

Yasenchak, Christopher A., primary, Bordoni, Rodolfo, additional, Patel-Donnelly, Dipti, additional, Larson, Timothy, additional, Goldschmidt, Jerome, additional, Boccia, Ralph V., additional, Cline, Vivian J.M., additional, Mamidipalli, Adrija, additional, Liu, Jingmin, additional, and Beck, Joseph T., additional

Published
2022
Full Text
View/download PDF

34. Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Author

Liu, Hongtao, primary, Sharon, Elad, additional, Karrison, Theodore G., additional, Zha, Yuanyuan, additional, Fulton, Noreen, additional, Streicher, Howard, additional, Sweet, Kendra, additional, Yaghmour, George, additional, Liu, Jane Jijun, additional, Jonas, Brian A., additional, Schimmer, Aaron D., additional, Grant, Steven, additional, Zeidan, Amer M., additional, Hildebrandt, Gerhard C., additional, Hourigan, Christopher S., additional, Lowrey, Christopher H., additional, Mattison, Ryan J., additional, Palmisiano, Neil, additional, Salhotra, Amandeep, additional, Tzachanis, Dimitrios, additional, Baer, Maria R., additional, Lin, Tara L., additional, Patel, Prapti, additional, Chen, Helen, additional, Stadler, Walter M., additional, Odenike, Olatoyosi, additional, Larson, Richard A., additional, Gajewski, Thomas F., additional, and Stock, Wendy, additional

Published
2022
Full Text
View/download PDF

35. ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Author

Hughes, Timothy, primary, Cortes, Jorge E., additional, Takahashi, Naoto, additional, Larson, Richard A., additional, Issa, Ghayas C., additional, Bombaci, Felice, additional, Ramscar, Nicholas, additional, Kapoor, Shruti, additional, Ifrah, Sophie, additional, and Hochhaus, Andreas, additional

Published
2022
Full Text
View/download PDF

36. Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting

Author

Gile, Jennifer Jane, primary, Bock, Allison M., additional, Tawfiq, Reema K., additional, Larson, Melissa C., additional, Poonsombudlert, Kittika, additional, Maliske, Seth M., additional, Maurer, Matthew J., additional, Cerhan, James R., additional, Kabat, Brian, additional, Gysbers, Brianna, additional, Smith, Katherine, additional, Hwang, Steven R, additional, Inwards, David J., additional, Paludo, Jonas, additional, Ansell, Stephen M., additional, Habermann, Thomas M., additional, Ayyappan, Sabarish, additional, Witzig, Thomas E., additional, Nowakowski, Grzegorz S., additional, Farooq, Umar, additional, and Wang, Yucai, additional

Published
2022
Full Text
View/download PDF

37. Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis

Author

Saygin, Caner, primary, Stauber, Jacob, additional, Aldoss, Ibrahim, additional, Sperling, Adam S., additional, Weeks, Lachelle D., additional, Luskin, Marlise R., additional, Knepper, Todd C., additional, Wanjari, Pankhuri, additional, Wang, Peng, additional, Lager, Angela, additional, Segal, Jeremy, additional, Kaumeyer, Benjamin, additional, Gurbuxani, Sandeep, additional, Venkataraman, Girish, additional, Cheng, Jason Xiaojun, additional, Eisfelder, Bartholomew, additional, Bohorquez, Oliver, additional, Patel, Anand Ashwin, additional, Odenike, Olatoyosi, additional, Larson, Richard A., additional, Godley, Lucy A., additional, Arber, Daniel A., additional, Ebert, Benjamin L., additional, Greally, John M., additional, Steidl, Ulrich G., additional, Shah, Bijal D., additional, and Stock, Wendy, additional

Published
2022
Full Text
View/download PDF

38. Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study

Author

Ruan, Jia, primary, Larson, Melissa C., additional, Chen, Zhengming, additional, Bennani, N. Nora, additional, Allen, Pamela B., additional, Jaye, David L, additional, Cohen, Jonathon B., additional, Chihara, Dai, additional, Vega, Francisco, additional, Inghirami, Giorgio, additional, Mou, Eric, additional, Casulo, Carla, additional, Mehta-Shah, Neha, additional, Martin, Peter, additional, Maurer, Matthew J., additional, Kahl, Brad S., additional, Lossos, Izidore S., additional, Flowers, Christopher R., additional, Cerhan, James R., additional, and Feldman, Andrew L., additional

Published
2022
Full Text
View/download PDF

40. Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/Refractory Multiple Myeloma

Author

Kumar, Anupama, primary, Rosenberg, Aaron S, additional, Padilla, Michelle, additional, Shah, Nina, additional, Sirianni, Lindsey, additional, Liu, Lin, additional, Cheng, Yuwei, additional, Pittman, Emily, additional, Tzachanis, Dimitrios, additional, Larson, Sarah, additional, Mulroney, Carolyn, additional, Ball, Edward D., additional, and Costello, Caitlin, additional

Published
2022
Full Text
View/download PDF

41. Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma

Author

Tawfiq, Reema K., primary, Larson, Melissa C., additional, Gile, Jennifer Jane, additional, Bock, Allison M., additional, Poonsombudlert, Kittika, additional, Maliske, Seth M., additional, Maurer, Matthew J., additional, Cerhan, James R., additional, Kabat, Brian, additional, Smith, Katherine, additional, Godby, Richard Curtis, additional, Paludo, Jonas, additional, Inwards, David J., additional, Ayyappan, Sabarish, additional, Ansell, Stephen M., additional, Habermann, Thomas M., additional, Witzig, Thomas E., additional, Nowakowski, Grzegorz S., additional, Farooq, Umar, additional, and Wang, Yucai, additional

Published
2022
Full Text
View/download PDF

42. Patients with Deleterious Germline Variants in STXBP2 Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel

Author

Leick, Mark B., primary, Han, Seunghun, additional, Gallagher, Kathleen M.E., additional, Silva, Harrison, additional, Martin, Grace, additional, Camp, Sabrina, additional, Chu, Hoyin, additional, Gillani, Riaz, additional, Kann, Michael C., additional, Choi, Bryan D., additional, Larson, Rebecca, additional, Phillips, Merle, additional, Kienka, Tamina, additional, Bailey, Stefanie R., additional, Graham, Charlotte, additional, Reilly, Christopher R., additional, Jan, Max, additional, Gonzalez, Elba, additional, Horick, Nora K., additional, Budka, Justin, additional, Filosto, Simone, additional, Shen, Rhine R., additional, Van Allen, Eliezer, additional, AlDubayan, Saud H, additional, and Maus, Marcela V., additional

Published
2022
Full Text
View/download PDF

43. Measures of Structural Racism Predict ICU Admission Following Intensive Chemotherapy for AML

Author

Abraham, Ivy, primary, Rauscher, Garth, additional, Patel, Anand Ashwin, additional, Monick, Sarah, additional, Burkhart, Madelyn, additional, Shah, Eshana, additional, Dave, Ami, additional, Kroll, Matthew, additional, Tsai, Stephanie B., additional, Berg, Stephanie, additional, Erra, Amani, additional, Gannamani, Vedavyas, additional, Zia, Maryam, additional, Larson, Melissa L., additional, Stock, Wendy, additional, Altman, Jessica K., additional, and Khan, Irum, additional

Published
2022
Full Text
View/download PDF

44. Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers

Author

Symes, Emily, primary, Hu, Zhihong, additional, Walker, Stephen K., additional, Sovani, Vishakha, additional, Lopez-Hisijos, Nicolas, additional, Aqil, Barina, additional, Alikhan, Mir, additional, Cotta, Claudiu V., additional, Harrop, Sean, additional, Lager, Angela, additional, Thakral, Beenu, additional, Riedell, Peter A., additional, Fitzpatrick, Carrie, additional, Thirman, Michael J., additional, Patel, Anand Ashwin, additional, Saygin, Caner, additional, Ondrejka, Sandra L., additional, Bishop, Michael R., additional, Behdad, Amir, additional, Gurbuxani, Sandeep, additional, Arber, Daniel A., additional, You, M. James, additional, Larson, Richard A., additional, Smith, Sonali M., additional, Hodgson, Yan Amber, additional, Kline, Justin, additional, Ku, Matthew, additional, and Venkataraman, Girish, additional

Published
2022
Full Text
View/download PDF

45. Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium

Author

Day, Jonathan R, primary, Larson, Melissa C., additional, Casulo, Carla, additional, Wang, Yucai, additional, Chihara, Dai, additional, Kahl, Brad S., additional, Martin, Peter, additional, Lossos, Izidore S., additional, Orellana-Noia, Victor M., additional, Burack, Richard, additional, Friedberg, Jonathan W., additional, Habermann, Thomas M., additional, Cerhan, James R., additional, Flowers, Christopher R., additional, Maurer, Matthew J., additional, and Link, Brian K., additional

Published
2022
Full Text
View/download PDF

46. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Author

Tefferi, Ayalew, Guglielmelli, Paola, Larson, Dirk R., Finke, Christy, Wassie, Emnet A., Pieri, Lisa, Gangat, Naseema, Fjerza, Rajmonda, Belachew, Alem A., Lasho, Terra L., Ketterling, Rhett P., Hanson, Curtis A., Rambaldi, Alessandro, Finazzi, Guido, Thiele, Juergen, Barbui, Tiziano, Pardanani, Animesh, and Vannucchi, Alessandro M.

Published
2014
Full Text
View/download PDF

48. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Author

Hans-Peter Horny, Cecilia Arana Yi, Celalettin Ustun, Cecilia C. S. Yeung, Jason Gotlib, Christina Cho, Tracy I. George, David R. Czuchlewski, Jessica Kohlschmidt, Amandeep Salhotra, Ryotaro Nakamura, Sheeja T. Pullarkat, Gerwin Huls, Linda B. Baughn, Robert S. Ohgami, Jenna M. Voutsinas, Cem Akin, Wolfgang R. Sperr, Guido Marcucci, Jason L. Hornick, Young L. Kim, Hanne Vestergaard, Qian Wu, Gautam Borthakur, Gregor Hoermann, Mark R. Litzow, Michael Boe Møller, Peter Valent, Dong Chen, Jacobien R. Hilberink, Miguel-Angel Perales, Melissa L. Larson, Thomas Kielsgaard Kristensen, Michael A. Linden, Ana Iris Schiefer, Philip M. Kluin, Daniel J. Weisdorf, Clara D. Bloomfield, Vinod Pullarkat, Michelle M Dolan, Se young Han, Nam K. Ku, H. Joachim Deeg, Krzysztof Mrózek, Sigurd Broesby-Olsen, Elizabeth A. Morgan, Lori Soma, Stem Cell Aging Leukemia and Lymphoma (SALL), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Male, EXPRESSION, medicine.medical_specialty, Myeloid, C-KIT MUTATIONS, PROGNOSTIC IMPACT, MINIMAL RESIDUAL DISEASE, ACUTE MYELOID-LEUKEMIA, Trisomy 8, RELAPSE, Gastroenterology, Translocation, Genetic, Internal medicine, medicine, Humans, Retrospective Studies, Chromosome Aberrations, Univariate analysis, Myeloid Neoplasia, business.industry, Core Binding Factors, Hematology, medicine.disease, GENE, CANCER, Leukemia, Myeloid, Acute, Leukemia, medicine.anatomical_structure, Chromosome abnormality, SURVIVAL, Hypodiploidy, Female, Hyperdiploidy, Trisomy, business
Abstract

Patients with core-binding factor (CBF) acute myeloid leukemia (AML), caused by either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22), have higher complete remission rates and longer survival than patients with other subtypes of AML. However, ∼40% of patients relapse, and the literature suggests that patients with inv(16) fare differently from those with t(8;21). We retrospectively analyzed 537 patients with CBF-AML, focusing on additional cytogenetic aberrations to examine their impact on clinical outcomes. Trisomies of chromosomes 8, 21, or 22 were significantly more common in patients with inv(16)/t(16;16): 16% vs 7%, 6% vs 0%, and 17% vs 0%, respectively. In contrast, del(9q) and loss of a sex chromosome were more frequent in patients with t(8;21): 15% vs 0.4% for del(9q), 37% vs 0% for loss of X in females, and 44% vs 5% for loss of Y in males. Hyperdiploidy was more frequent in patients with inv(16) (25% vs 9%, whereas hypodiploidy was more frequent in patients with t(8;21) (37% vs 3%. In multivariable analyses (adjusted for age, white blood counts at diagnosis, and KIT mutation status), trisomy 8 was associated with improved overall survival (OS) in inv(16), whereas the presence of other chromosomal abnormalities (not trisomy 8) was associated with decreased OS. In patients with t(8;21), hypodiploidy was associated with improved disease-free survival; hyperdiploidy and del(9q) were associated with improved OS. KIT mutation (either positive or not tested, compared with negative) conferred poor prognoses in univariate analysis only in patients with t(8;21).

Published
2021

49. Patients with Deleterious Germline Variants in STXBP2 Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel

Author

Mark B. Leick, Seunghun Han, Kathleen M.E. Gallagher, Harrison Silva, Grace Martin, Sabrina Camp, Hoyin Chu, Riaz Gillani, Michael C. Kann, Bryan D. Choi, Rebecca Larson, Merle Phillips, Tamina Kienka, Stefanie R. Bailey, Charlotte Graham, Christopher R. Reilly, Max Jan, Elba Gonzalez, Nora K. Horick, Justin Budka, Simone Filosto, Rhine R. Shen, Eliezer Van Allen, Saud H AlDubayan, and Marcela V. Maus

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

Catalog

Books, media, physical & digital resources
See catalog results